The FDA on April 26, 2012 granted accelerated approval to AFINITOR® for the treatment of adults with renal angiomyolipoma, associated with tuberous sclerosis complex (TSC), who do not require immediate surgery. AFINITOR® is a product of Novartis Pharmaceuticals.
Bottom Ad
Advertisement
Subscribe
